Hensley Mark Earl has filed 3 insider transactions across 1 company since May 2025.
Most recent transaction: a grant/award of 188315 shares of HERON THERAPEUTICS, INC. /DE/ ($HRTX) on January 30, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 30, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Hensley Mark Earl | Chief Operating Officer | A | Restricted Stock Units | 188315 | $0.00 | 188,315.0000 | 183,362,522 | 9999.99% | 0.10% |
| Jan. 30, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Hensley Mark Earl | Chief Operating Officer | A | Performance Stock Units | 188314 | $0.00 | 188,314.0000 | 183,362,522 | 9999.99% | 0.10% |
| May 6, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Hensley Mark Earl | Chief Operating Officer | A | Restricted Stock Units | 500000 | $0.00 | 500,000.0000 | 152,329,588 | 9999.99% | 0.33% |